MMP2过表达在子宫内膜腺癌的临床意义  

Clinical significance of MMP2 overexpression in endometrial adenocarcinoma

作　　者：李姝君[1] 沈湘[1] 杨志雄[1] 吴爱兵[1] 唐志[1] 黎明春[1] 令映霞 

机构地区：[1]广东医学院附属医院肿瘤中心,广东湛江524001 [2]广州医科大学第一附属医院妇产科,广东广州510120

出　　处：《南方医科大学学报》2014年第3期423-425,共3页Journal of Southern Medical University

基　　金：国家自然科学基金(81301894);国家自然青年基金项目(81301894)~~

摘　　要：目的：探讨MMP2表达与子宫内膜腺癌临床参数和预后之间相关性。方法我们收集了81例子宫内膜腺癌患者石蜡标本。这些患者的年龄在32-80岁之间。随后，利用免疫组化SP方法检测了81例子宫内膜腺癌中MMP2表达情况。最后，我们使用SPSS软件统计分析了MMP2表达与与子宫内膜腺癌进展和预后之间相关性。结果MMP2在子宫内膜腺癌胞浆中表达。此外，过表达的MMP2与子宫内膜腺癌分化程度（P=0.015）以及预后（P=0.041）呈负性相关。结论MMP2过表达是子宫内膜腺癌患者的一个恶性标志物。Objective To explore the expression of MMP2 and its correlation with the clinical features and prognosis of endometrial adenocarcinoma. Methods We collected paraffin- embedded samples from 81 patients with endometrial adenocarcinoma aged 32 to 80 years to examine the expression of MMP2 using immunohistochemistry. The correlation of MMP2 expression with the clinical characteristics and prognosis of the patients was analyzed. Results MMP2 protein was expressed in the cytoplasm of the tumor cells. MMP2 over-expression was negatively correlated with tumor differentiation （P=0.015） and prognosis （P=0.041） of endometrial adenocarcinoma. Conclusion MMP2 over-expression is a potential malignant biomarker in endometrial adenocarcinoma.

关 键 词：子宫内膜腺癌 MMP2 恶性标志物 MMP2 

分 类 号：R737.33[医药卫生—肿瘤]